Medivation/Astellas prostate cancer drug gains US priority review
This article was originally published in Scrip
Executive Summary
Medivation investors were keen on the six-month priority review the firm and its Tokyo-based partner Astellas Pharma won from the US FDA on the companies' new drug application (NDA) for enzalutamide (MDV3100), which is being considered as a treatment for men with castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.